Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease
- PMID: 36649216
- DOI: 10.1021/acs.jmedchem.2c01410
Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease
Abstract
c-Jun N-terminal kinases (JNKs) are involved in the pathogenesis of various diseases. In particular, JNK3 and not JNK1/2 is primarily expressed in the brain and plays a key role in mediating neurodegenerative diseases like Parkinson's disease (PD). Due to the sequence similarity of JNK isoforms, developing isoform-selective JNK3 inhibitors to evaluate their biological functions and therapeutic potential in PD has become a challenge. Herein, docking-based virtual screening and structure-activity relationship studies identified 25c with excellent inhibitory activity against JNK3 (IC50 = 85.21 nM) and exhibited an over 100-fold isoform selectivity for JNK3 over JNK1/2 and remarkable kinase selectivity. 25c showed neuroprotective effects on in vitro and in vivo PD models by selectively inhibiting JNK3. Meanwhile, 25c showed an ideal blood-brain barrier permeability and low toxicity. Overall, this study provided a valuable molecular tool for investigating the role of JNK3 in PD and a solid foundation for developing JNK3-targeted drugs in PD treatment.
Similar articles
-
Discovery of a Potent and Selective JNK3 Inhibitor with Neuroprotective Effect Against Amyloid β-Induced Neurotoxicity in Primary Rat Neurons.Int J Mol Sci. 2021 Oct 14;22(20):11084. doi: 10.3390/ijms222011084. Int J Mol Sci. 2021. PMID: 34681742 Free PMC article.
-
Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.J Med Chem. 2019 Jul 25;62(14):6645-6664. doi: 10.1021/acs.jmedchem.9b00537. Epub 2019 Jul 15. J Med Chem. 2019. PMID: 31268308
-
Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's disease.Eur J Med Chem. 2023 Jan 5;245(Pt 1):114894. doi: 10.1016/j.ejmech.2022.114894. Epub 2022 Nov 2. Eur J Med Chem. 2023. PMID: 36343411
-
c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. doi: 10.1517/13543776.2015.1039984. Epub 2015 May 19. Expert Opin Ther Pat. 2015. PMID: 25991433 Review.
-
A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer's Disease: Investigating Structure through Docking Studies.Biomedicines. 2021 Oct 9;9(10):1431. doi: 10.3390/biomedicines9101431. Biomedicines. 2021. PMID: 34680547 Free PMC article. Review.
Cited by
-
Discovery of Pyrimidine- and Coumarin-Linked Hybrid Molecules as Inducers of JNK Phosphorylation through ROS Generation in Breast Cancer Cells.Molecules. 2023 Apr 13;28(8):3450. doi: 10.3390/molecules28083450. Molecules. 2023. PMID: 37110684 Free PMC article.
-
Novel Tryptanthrin Derivatives with Selectivity as c-Jun N-Terminal Kinase (JNK) 3 Inhibitors.Molecules. 2023 Jun 16;28(12):4806. doi: 10.3390/molecules28124806. Molecules. 2023. PMID: 37375361 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
